Article Sidebar
Published:
Jan 23, 2024Keywords:
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Open access articles published in the Journal of Agriculture, Science and Technology are under the terms of the Creative Commons Attribution (CC BY) License which permits use, distribution and reproduction in any medium, provided the original work is properly cited. The CC BY license permits commercial and non-commercial re-use of an open-access article, as long as the author is properly attributed.
Copyright on any research article published in the Journal of Agriculture, Science and Technology is retained by the author(s). The authors grant the Journal of Agriculture, Science and Technology with a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its original authors, citation details and publisher are identified.
Use of the article in whole or in part in any medium requires proper citation as follows:
Title of Article, Names of the Author, Year of Publication, Journal Title, Volume (Issue) and page. Links to the final article on the JSRE website are encouraged.
The Creative Commons Attribution License does not affect any other rights held by authors or third parties in the article, including without limitation the rights of privacy and publicity. Use of the article must not assert or imply, whether implicitly or explicitly, any connection with, endorsement or sponsorship of such use by the author, publisher or any other party associated with the article.
For any reuse or distribution, users must include the copyright notice and make clear to others that the article is made available under a Creative Commons Attribution license, linking to the relevant Creative Commons web page. Users may impose no restrictions on the use of the article other than those imposed by the Creative Commons Attribution license.
To the fullest extent permitted by applicable law, the article is made available as is and without representation or warranties of any kind whether express, implied, statutory or otherwise and including, without limitation, warranties of title, merchantability, fitness for a particular purpose, non-infringement, absence of defects, accuracy, or the presence or absence of errors.
Main Article Content
The effects of non-bitter Cucumis metuliferus fruit extract on blood sugar of high-fat/fructose diet and streptozotocin-induced type II diabetic Wistar Albino rats
Abstract
Globally, diabetes mellitus (DM) remains one of the leading debilitating non-communicable diseases, with its prevalence projected to increase from 8.8% in 2015 to 10.0% in 2030. The management of diabetes mellitus remains a major challenge, and the number of diabetes-related deaths is projected to rise from 3.1 million in 2015 to 4.2 million in 2030. This continues to be a public health concern, particularly in developing countries where the majority of people are poor and predominantly live in rural areas, facing challenges in accessing healthcare services. However, the non-bitter Cucumis metuliferus fruit is being used for managing type 2 diabetes mellitus by some communities in Kenya, although its therapeutic benefits have not been adequately studied and proven. The study aimed to determine the effects of non-bitter Cucumis metuliferus fruit extract on blood sugar in high-fat/fructose diet and streptozotocin-induced type II diabetic Wistar albino rats. This study adopted an experimental laboratory-based design. A sample size of 64 male Wistar albino rats, aged 5 weeks and weighing between 90 and 130 grams, was randomly assigned to two major study groups: the control group and the experimental group. The experimental group received a high-fat/fructose diet plus streptozotocin (STZ) injection to induce diabetes mellitus, whereas the control group received a standard rodent pellet diet plus 0.9% normal saline injection. The experimental group was further divided into a positive control group treated with pioglitazone (the standard drug) at a dose of 20 mg/kg body weight, a low-dose CMFE group at 200 mg/kg body weight, and a high-dose CMFE group at 400 mg/kg body weight. Fasting blood sugar (FBS), oral glucose tolerance test (OGTT), and haemoglobin A1c (Hb A1c) tests were used as indicators, and the results were compared between the groups. The study findings revealed a significant statistical rise (P <0.001) of FBS in the treatment group after induction of type II DM, followed by a decline to pre-induction levels after treatment. Similarly, there was a statistically significant increase (P <0.001) of the OGTT after induction of type II DM, with the OGTT declining to pre-induction levels following treatment (P =0.106). The findings on both the FBS and OGTT tests indicate that treatment with CMFE controlled the blood sugar. Consequently, there was no significant difference (P =0.712) in Hb A1c test results between the control group and the treatment group at the end of the experiment, indicating that treatment with CMFE had a long-term control effect on blood sugar. This study concludes that the non-bitter CMFE possesses both short-term and long-term hypoglycemic properties in type II diabetes mellitus.
